Urology | Specialty

Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial Cancer

September 30th 2021

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Dr. Choueiri on the Results of the KEYNOTE-564 Study in RCC

September 13th 2021

Toni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.

Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

September 13th 2021

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

18F-DCFPyL Could Become a Key Diagnostic Tool for Biochemical Recurrence in Prostate Cancer

September 13th 2021

18F-DCFPyL, a PET prostate specific membrane antigen targeting agent, demonstrated statistically significant potential in detecting biochemical recurrence in men with prostate cancer.

Panvac Plus BCG Does Not Significantly Delay Recurrence in Advanced NMIBC

September 13th 2021

The addition of a recombinant pox-viral vector vaccine Panvac™ to bacillus Calmette-Guérin did not significantly improve clinical outcomes for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Avelumab Plus BCG Induction Shows Favorable Tolerability in BCG-Unresponsive NMIBC

September 13th 2021

The addition of avelumab to Bacillus Calmette-Guerin induction therapy appeared to be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

September 12th 2021

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Durvalumab/Vicineum Combo Shows Early Safety, Activity in High-Grade NMIBC

September 11th 2021

The combination of durvalumab and Vicineum was found to be well tolerated and to elicit complete responses in patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer.

Dr. Tewari on the Benefits of Robotic Radical Prostatectom​y​ in Prostate Cancer

September 10th 2021

Ashutosh K. Tewari, MD, discusses the benefits of robotic radical prostatectom​y in prostate cancer.

Patients With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10th 2021

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

Enfortumab Vedotin Shows Superior Efficacy Over Chemo in Previously Treated Urothelial Carcinoma

February 13th 2021

February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.

Avelumab as Frontline Maintenance Maintains OS Benefit in Japanese Subgroup of Advanced Urothelial Cancer

February 11th 2021

February 11, 2021 - Avelumab as frontline maintenance therapy plus best supportive care showed a favorable benefit-risk balance in Japanese patients with advanced urothelial cancer that did not progress on first-line chemotherapy.


January 29th 2021


Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

October 14th 2020

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma

September 20th 2020

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

Immune-Related Biomarkers Linked With OS Benefits of Frontline Maintenance Avelumab in Advanced Urothelial Carcinoma

September 20th 2020

Overall survival benefits of frontline maintenance treatment with avelumab in patients with advanced urothelial cancer were found to be positively associated with biomarkers of immune activity and negativity linked with biomarkers of tumor homeostasis and chronic inflammation.

Bright Future in Advanced Urothelial Cancer

August 26th 2020

Sequencing Considerations in mUC after Frontline IO

August 26th 2020